Trials / Completed
CompletedNCT05450575
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
A Prospective, Observational Study of Factors Affecting Blood Pressure and Blood Lipids After Treatment With Amosartan Q Tablet in Hypertension Patients With Dyslipidemia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 5,400 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study was to evaluate the therapeutic effect and safety of amosartan Q tablet administration in adult patients with hypertension and dyslipidemia. During the routine medical visit, Amosartan Q tablets were administered to patients in need of blood pressure/LDL-C control according to the investigator's judgment. In this study, effectiveness and safety information of treatment of Amosartan Q tablets was followed for 6 months (up to 12 months), and observation of the target patients was terminated after collecting relevant data. As this study was a non-interventional observational study, all patients received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.
Detailed description
This study was a multicenter, prospective, non-interventional, observational study of factors affecting blood pressure and blood lipids after treatment with Amosartan Q tablet in hypertension patients with dyslipidemia. Data was collected from patients receiving routine treatment at hospitals in South Korea. Each patient visited the institution according to the protocol that designed the follow-up visits for six months to examine the effectiveness and safety of Amosartan Q tablet. This study approved by the institutions' IRBs and was conducted in compliance with clinical research ethics regulations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Amosartan Q tablet | Amlodipine, Losartan, Rosuvastatin |
Timeline
- Start date
- 2018-04-17
- Primary completion
- 2021-07-20
- Completion
- 2021-07-20
- First posted
- 2022-07-08
- Last updated
- 2022-07-08
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05450575. Inclusion in this directory is not an endorsement.